Literature DB >> 31844009

Comparative Evaluation of the In Vitro Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant Pseudomonas aeruginosa.

Elias M Mullane1, Lindsay M Avery1, David P Nicolau2,3.   

Abstract

The in vitro activity of WCK 5222 (cefepime-zidebactam) was compared to that of several available combination therapies among 30 clinical carbapenem-resistant Pseudomonas aeruginosa (CRP) strains using gradient diffusion strips. The combinations included nonsusceptible β-lactams (cefepime, ceftolozane-tazobactam, and meropenem) with amikacin and fosfomycin. WCK 5222 MICs ranged from 2 to 32 mg/liter, and 97% were ≤16 mg/liter, while 105/146 (72%) combinations demonstrated inhibition below established susceptibility breakpoints. WCK 5222 monotherapy may be preferred over the combinations assessed for CRP infections.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Pseudomonas aeruginosa; WCK 5222; beta-lactams; carbapenem resistant; gradient diffusion; synergy

Mesh：

Substances：

Year:  2020        PMID： 31844009      PMCID： PMC7038276          DOI： 10.1128/AAC.01669-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model.

Authors:  Marguerite L Monogue; Jennifer Tabor-Rennie; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

2.  Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals.

Authors:  Mariana Castanheira; Timothy B Doyle; Caitlin J Smith; Rodrigo E Mendes; Helio S Sader
Journal:  J Antimicrob Chemother       Date:  2019-09-01       Impact factor: 5.790

3.  Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234.

Authors:  Krisztina M Papp-Wallace; Nhu Q Nguyen; Michael R Jacobs; Christopher R Bethel; Melissa D Barnes; Vijay Kumar; Saralee Bajaksouzian; Susan D Rudin; Philip N Rather; Satish Bhavsar; Tadiparthi Ravikumar; Prasad K Deshpande; Vijay Patil; Ravindra Yeole; Sachin S Bhagwat; Mahesh V Patel; Focco van den Akker; Robert A Bonomo
Journal:  J Med Chem       Date:  2018-04-20       Impact factor: 7.446

4.  Mechanisms of high-level ceftolozane/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin.

Authors:  Wonhee So; James Shurko; Ralph Galega; Rod Quilitz; John N Greene; Grace C Lee
Journal:  J Antimicrob Chemother       Date:  2019-01-01       Impact factor: 5.790

5.  Feasibility of routine synergy testing using antibiotic gradient diffusion strips in the clinical laboratory.

Authors:  Lindsay M Avery; David P Nicolau
Journal:  J Antimicrob Chemother       Date:  2018-08-01       Impact factor: 5.790

6.  WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.

Authors:  Helio S Sader; Paul R Rhomberg; Robert K Flamm; Ronald N Jones; Mariana Castanheira
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

7.  Clinical relevance of in vitro synergistic activity of antibiotics for multidrug-resistant Gram-negative infections: A systematic review.

Authors:  Konstantinos Z Vardakas; Florentia Athanassaki; Vassiliki Pitiriga; Matthew E Falagas
Journal:  J Glob Antimicrob Resist       Date:  2019-01-15       Impact factor: 4.035

8.  Single β-lactams versus combinations as empiric therapy for infections with Pseudomonas aeruginosa: assessing the in vitro susceptibility.

Authors:  Safa S Almarzoky Abuhussain; Christina A Sutherland; David P Nicolau
Journal:  Infect Dis (Lond)       Date:  2019-10-09

9.  Potency of parenteral antimicrobials including ceftolozane/tazobactam against nosocomial respiratory tract pathogens: considerations for empiric and directed therapy.

Authors:  Christina A Sutherland; David P Nicolau
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

10.  A Combination Antibiogram Evaluation for Pseudomonas aeruginosa in Respiratory and Blood Sources from Intensive Care Unit (ICU) and Non-ICU Settings in U.S. Hospitals.

Authors:  Laura Puzniak; Daryl D DePestel; Arjun Srinivasan; Gang Ye; John Murray; Sanjay Merchant; C Andrew DeRyke; Vikas Gupta
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191
View more
  3 in total

Review 1.  New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review.

Authors:  Angela Raffaella Losito; Francesca Raffaelli; Paola Del Giacomo; Mario Tumbarello
Journal:  Antibiotics (Basel)       Date:  2022-04-26

2.  Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate.

Authors:  Xiaolei Pan; Xinrui Zhao; Yuqin Song; Huan Ren; Zhenyang Tian; Qi'an Liang; Yongxin Jin; Fang Bai; Zhihui Cheng; Jie Feng; Weihui Wu
Journal:  Microbiol Spectr       Date:  2022-02-23

Review 3.  Losing the Battle but Winning the War: Can Defeated Antibacterials Form Alliances to Combat Drug-Resistant Pathogens?

Authors:  Song Oh; Raymond Chau; Anh T Nguyen; Justin R Lenhard
Journal:  Antibiotics (Basel)       Date:  2021-05-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.